Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Heron Therapeutics (HRTX) over the last 4 years, with Sep 2025 value amounting to $229.4 million.

  • Heron Therapeutics' Total Non-Current Liabilities fell 11.96% to $229.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.4 million, marking a year-over-year decrease of 11.96%. This contributed to the annual value of $266.2 million for FY2024, which is 3.88% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Total Non-Current Liabilities is $229.4 million, which was down 11.30% from $258.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Total Non-Current Liabilities registered a high of $266.2 million during Q4 2024, and its lowest value of $229.4 million during Q3 2025.
  • In the last 3 years, Heron Therapeutics' Total Non-Current Liabilities had a median value of $256.2 million in 2023 and averaged $251.9 million.
  • As far as peak fluctuations go, Heron Therapeutics' Total Non-Current Liabilities increased by 8.34% in 2024, and later declined by 11.96% in 2025.
  • Heron Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $237.1 million in 2022, then climbed by 8.05% to $256.2 million in 2023, then climbed by 3.88% to $266.2 million in 2024, then declined by 11.96% to $229.4 million in 2025.
  • Its last three reported values are $229.4 million in Q3 2025, $258.6 million for Q2 2025, and $263.5 million during Q1 2025.